onset of mouse myogenesis ͉ satellite cell differentiation T he regulation of transcription factors that distinguish a progenitor cell from its tissue derivatives is an important facet of stem cell biology. Myogenesis provides a paradigm in which this level of control can be explored (1) . Skeletal muscle progenitor cells are characterized by the expression of Pax3 and Pax7. These multipotent stem cells are present in the epithelial dermomyotome of the embryonic somite and subsequently enter the underlying myotome, the first differentiated muscle to form. Pax3/7-positive myogenic progenitors constitute a self-renewing population of cells that are essential for all subsequent skeletal muscle growth and contribute the satellite cells, required for regeneration of adult skeletal muscle. At the onset of myogenesis, Pax3-positive cells also migrate from the hypaxial domain of the dermomyotome to sites, such as those in the limbs, where skeletal muscles will form. Pax7 is subsequently up-regulated in these cells, which down-regulate the Pax genes before differentiation. The myogenic determination genes Myf5 (2) and MyoD (3) are direct targets of Pax3/7, which thus direct progenitors into the myogenic program. Such cells will proliferate as myoblasts and then differentiate after activation of Myogenin, another myogenic regulatory gene of the MyoD family. This is exemplified by the muscle satellite cell, which lies under the basal lamina of adult muscle fibers (4). On injury or in culture, before differentiation, these cells down-regulate Pax7 and Pax3, which is expressed in a subset of muscles at this stage (5) . Low-level expression of Pax3/7 does not completely inhibit activation of Myogenin and muscle genes such as Troponin T (6), but the adverse effect of maintaining expression of these proteins is immediately evident when they are overexpressed, as reported for Pax7, which blocks differentiation (7) . In addition to transcriptional repression of Pax3 and Pax7, the Pax3 protein is subject to a specific degradative pathway through monoubiquitination in satellite cells. When this is prevented, expression of differentiation markers is reduced (8) .
In addition to regulation at the protein level, it is becoming increasingly evident that microRNA (miRNA) regulation of mRNAs also represents an effective way of rapidly interfering with function. This takes place when the miRNA, as part of the RNA-induced silencing complex (RISC), targets the 3Ј-UTR of transcripts by imperfect base pairing and functions to inhibit translation either at the initiation stage or at postinitiation steps. In some cases, degradation of the target mRNA is also a mechanism or consequence of miRNA-mediated suppression (9) .
Although many miRNAs are expressed across multiple lineages or tissues (10, 11) , some miRNAs are lineage restricted. This is the case for the muscle-specific ''myomiRs,'' which include miRNA-1 (miR-1) and its variant miR-206, along with miR-133, which is closely linked and coexpressed with both. Somitic expression of these miRNAs is restricted to the myotome, and this is consistent with their transcriptional regulation by MyoD and by MEF2, also implicated in skeletal myogenesis (12) (13) (14) . Through the validation of some of the targets of these miRNAs, roles for them have been proposed in regulating the balance between proliferating and differentiating myoblasts by SRF/HDAC4 (15) or via an effect on DNA polymerase II (16) . However, the potential role of miRNAs in repressing the expression of the key upstream regulators, Pax3 and Pax7, has not been addressed. In this article, we predict and validate miR-27 as a regulator of Pax3. This miRNA is expressed both in differentiating muscle masses, such as the myotome, in the embryo in differentiating satellite cells in the adult. It targets the 3Ј-UTR of Pax3 mRNA and affects Pax3 expression in vitro and in vivo, with consequences for the onset of skeletal muscle differentiation.
gest the target site is accessible (Table S1 ). miR-27 includes miR-27a and miR-27b, which are transcribed from different chromosomes and differ by only one 3Ј nucleotide. In the following experiments, similar results were obtained for miR-27a (Fig. S1 ). Functional tests in 293 cells, using a standard luciferase assay, demonstrate that miR-27b directly targets the Pax3 3Ј-UTR, specifically through the predicted site, as shown by mutation (Fig. 1B) . We then verified the expression of miR-27b in the mouse embryo. At embryonic day 10.5 (E10.5) ( Fig. 2A) , it is expressed at a number of sites, including the somites. In immature, caudal somites, it is present in the ventral sclerotome, where Pax3 expression is down-regulated, but is excluded from the Pax3-positive dorsal dermomytome (Fig. 2B) . In more mature interlimb somites, miR-27b has accumulated in the myotome (Fig. 2C) , where skeletal muscle is forming, as indicated by Myogenin (MyoG) labeling (Fig. 2D) .
Manipulation of miR-27b by using a lentivirus expression vector in somite explants leads to down-regulation of Pax3, but not Pax7, in transduced cells (Fig. 3A) . When miR-27b is expressed in Pax3-positive cells as a conditional transgene in vivo, this resulted in a 2.5-fold increase in miR-27b expression, assessed in the limb buds by quantitative real-time PCR (qRT-PCR) (Fig. S3) . Pax3 is reduced, exemplified by the reduction in Pax3-positive cells in forelimb buds (52 Ϯ 9% of controls) ( Fig.  3 B and C) . Pax3 is required for the survival and migration of cells from the hypaxial dermomyotome to the limb buds (1, 2, 20) . These results therefore suggest that Pax3 is affected by the presence of miR-27b. Lbx1, which also marks these migrating cells (21) , was detectable in more cells (72 Ϯ 9% of controls) than Pax3 (Fig. 3B) , suggesting that in the transgenic embryos there is also ongoing down-regulation of Pax3 in the limb buds. We went on to analyze the balance between Pax3-positive progenitors and Myogenin-positive differentiating myogenic cells in limb buds. At E11.5, there is a striking shift toward differentiating cells (Fig. 3 D and E) . In this situation, therefore, a reduction in Pax3 levels favors premature differentiation of those myogenic progenitor cells that have migrated into the limb bud. Promotion of differentiation is also detectable in the myotome of the somite at this stage ( Fig. 3 D and E) .
We carried out the opposite experiment in adult muscle satellite cells by inhibiting miR-27b activity. Satellite cells from the diaphragm were isolated by flow cytometry from Pax3 GFP/ϩ mice (5). In culture, these cells continue to express Pax3 transcripts, which are still present at lower levels after day 5, whereas Myogenin transcripts accumulate at this time (Fig. 4A ).
As cells prepare to differentiate by 3 days, miR-27b has increased. Similar results are shown for differentiating C2 myoblasts (Fig. S4) . In contrast, miR-1 only accumulates later, indicative of its involvement in differentiated muscle (Fig. 4B) .
When an inhibitor to miR-27b is added to the culture, Pax3 protein increases, whereas Troponin T, a marker of differentiated muscle cells, decreases. Pax7, which is not a predicted target of miR-27b, was not affected (Fig. 4C ). Pax3 transcript levels were not significantly affected (Fig. 4D) . The effect of anti-miR27b inhibitors on skeletal muscle differentiation is illustrated in Fig. 5 for Myogenin and Troponin T. After 4 days in culture, the levels of these differentiation markers are reduced and proliferation is higher, as indicated by the number of DAPI-positive nuclei ( Fig. 5 A and B) . In satellite cells, from Pax3 GFP/flox null mice, no effect of miR-27b inhibition on differentiation is observed, showing that it acts primarily through Pax3 (Fig. 5C ). After 5 days, in Pax3 GFP/ϩ cultures, Myogenin, which is expressed at the onset of differentiation, is now higher and Troponin T begins to be detectable, whereas in control satellite cell cultures large Troponin T-positive myotubes have formed in the control (Fig. 5 D and E) . At this stage, the fusion index is reduced after transfection of anti-miR-27b inhibitors (Fig. 5F ). These experiments show that, when Pax3 protein levels are maintained by preventing the effect of miR-27b on Pax3 mRNA, differentiation of satellite cells is delayed.
To look at effects on muscle satellite cell differentiation in vivo, the pectoralis muscle, which includes Pax7-positive satellite cells also expressing Pax3 (6), was injured by injection with cardiotoxin together with anti-miR-27b or control antagomirs. After 6 days, control injured muscle had regenerated to form new muscle fibers, with reconstitution of Pax7-positive satellite cells under the basal lamina (Fig. 6A) . Some of these cells (10%) also express Pax3 (Fig. 6 B and C) . In the presence of the antagomir, more satellite cells that coexpress Pax3 and Pax7 (40%) are present ( Fig. 6 B and C) , showing that Pax3 expression in activated satellite cells (8) is maintained. In addition, muscle injected with anti-miR-27b antagomirs had smaller fibers, indicative of a delay in regeneration (Fig. 6D) . Fibers with more Pax3-positive cells are notably smaller in diameter, in keeping with a more immature state.
Discussion
We show that the 3Ј-UTR of Pax3 mRNA is a target of miR-27. This is illustrated by standard luciferase assays in cell culture and by overexpression of miR-27 in somite explants or downregulation of miR-27 in muscle satellite cells. In the context of skeletal myogenesis, in the embryo, this miRNA is notably absent from the epithelial dermomyotome where Pax3-positive myogenic stem cells are present. As the skeletal muscle of the myotome forms from Pax3-expressing cells, derived from the dermomyotome, miR-27 is up-regulated. (22), or by modulation of Notch (23, 24) or TGF␤/myostatin signaling (25) . Manipulation of miR-27 expression in the embryo also affects Pax3 function before myogenesis; for example, at the level of migration of Pax3-positive progenitor cells from the somite to the limb bud. Here too, overexpression of miR-27 results in a specific downregulation of Pax3, with less effect on Lbx1, also expressed in these cells (21) . Lbx1 mRNA is not predicted to be a target of miR-27.
In adult muscle satellite cells, miR-27 is expressed, when Pax3 transcripts are still present, just before differentiation. In these myogenic progenitor cells, inhibitors to miR-27 delay the onset of skeletal muscle differentiation, in keeping with results that indicate an inhibitory effect of Pax3 on this process (8) . These results underline a role for Pax3, as distinct from Pax7 that is not affected by miR-27, in adult skeletal muscle myogenesis. In vivo observations on injured muscle also support a role for Pax3 and show that interference with its down-regulation by miR-27 delays regeneration. miR-27 may well have other targets, some of which may be important in the myogenic context; however, altering miR-27 activity on different stages of myogenesis, in the embryo and in adult satellite cells, strongly suggests that the negative regulation of Pax3 protein production is an important aspect of its function. This is also indicated by the results on satellite cells for a Pax3 GFP/flox -null mouse (26) where miR-27b inhibition no longer delays differentiation in the absence of Pax3.
Other miRNAs, miR-1/miR-206 and miR-133, that show skeletal muscle specificity, have been proposed to interfere with proliferation/differentiation of myogenic cells through effects on SRF/HDAC4 (15) or DNA polymerase II (16) . There is a potential target site in the 3Ј-UTR of Pax3 mRNA for miR-1/ miR-206. However, in our hands, miR-1 did not have as robust an effect as miR-27 in the standard luciferase assay. In addition, as we show, miR-1 accumulates after miR-27b, in differentiating satellite cells. Our results identify miR-27 as an important player in skeletal myogenesis, through its control of the 3Ј-UTR of Pax3 mRNA.
Materials and Methods
DNA Constructs. The 3Ј-UTR of the Pax3 transcript was amplified by PCR by using forward 5Ј-AAAAGCGGCCGCGTTTAAACGAGAAGATTCTTCATGTCTA-3Ј and reverse 5Ј-AAAACTCGAGGTTTAAACTAGGGGGTAGTTCCTCCT-3Ј primers, cloned into the pGEMT-Easy vector (Promega), and the sequence was verified. The predicted miR-27b ''seed'' site was mutated with mutagenic primers 5Ј-GCTGATCTTGCCCCTAACCCCGAATTGTCCCAGCATGACC-3Ј and 5Ј-GATCT-TGCCCCTAACCCCCTTTTGTCCCAGCATGACC-3Ј by using the QuickChange Multisite mutagenesis kit (Stratagene); mutations were confirmed by sequence analysis. The wild-type and mutated 3Ј-UTRs were subcloned into the NotI-XhoI site of the psicheck-2 vector (Promega). The miR-27b precursor sequence was amplified from genomic DNA by PCR using forward 5Ј-AAAAGTCGACCGAAGATGCTCACCAGCCCTT-3Ј and reverse 5Ј-AAAAGTC-GACGGCAGTGGCCTCTGCCTGGC-3Ј primers and cloned into the pGEMT-Easy vector. The verified sequence was subcloned into either the SalI site of pLenti-PGK-GFP (for explant transduction) or blunt-end ligated into the EcoRV site of pBSKIsceIGFP vector (for transgenesis), such that the stem-loop precursor sequence was located in the 3Ј-UTR of GFP (GFP-miR-27b), as described for enhanced expression of RNAi in refs. 27 and 28. Insertion of EGFP into pBSKIsceI (29) was by HindIII cloning of an amplified EGFP PCR product from pIRES2-EGFP (Clontech) using forward 5Ј-AAAAAGCTTCACAACGATGGTGAG-CAAGGG-3Ј and reverse 5Ј-AAAAAAGCTTTTACTTGTACAGCTCGTCCAT-3Ј primers. Sequence and orientation were confirmed. Transfections. 293 cells were seeded at 1.0 ϫ 10 4 cells per well of a 12-well plate and grown for 24 h. A total of 50 ng of the appropriate psicheck-2 luciferase reporter construct was cotransfected with 20 nM final concentration of either double-stranded RNA oligonucleotides designed to mimic miR-27b, anti-miR27b molecules, or their corresponding negative controls (Ambion) using Lipofectamine 2000 (Invitrogen). Twelve hours after transfection, the medium was changed and cells were grown for an additional 24 h before assay. Pax3 GFP/ϩ sorted cells were reverse transfected with the oligonucleotides by using RNAiMax (Invitrogen). Twelve hours after transfection, the medium was changed and cells were grown for the indicated periods before assay. Oligonucleotides were transfected efficiently and were stable throughout the course of the experiments (Fig. S5) .
Luciferase Assay. Luminescent signals arising from psicheck-2 transfected cells were quantified by using the Dual Luciferase assay system (Promega) with a GloMax luminometer (Promega). All values are given relative to transfections with the appropriate negative control oligonucleotide.
In Situ Hybridization. Embryos were harvested and fixed for 24 h in 4% paraformaldehyde, washed 3 times in PBS, and stored in methanol for a minimum of 24 h. Endogenous miR-27b was detected by using a locked nucleic acid (LNA) probe against miR-27b (31). Prehybridization and hybridization was with 60% formamide, at 57°C. After washes, embryos were incubated with anti-digoxigenin (DIG) antibody (Roche) overnight at 4°C and washed extensively for 5 days before staining with BM Purple AP substrate (Roche). For optimal signal-to-background ratios, DIG-labeled LNA probes were recycled 2 additional times.
RNA and Protein Analysis. Total RNA was harvested from cells by using TRIzol reagent (Invitrogen). Detection of miRNAs from samples by quantitative RT-PCR was performed by using the miRcury LNA MicroRNA PCR system (Exiqon) according to the manufacturer's instructions. Amplification of U6 RNA was used to normalize the data. For detection of mRNAs, total RNA was reverse transcribed with a random primer (Ambion) by using SuperScript II reverse transcriptase (Invitrogen). Primers were forward 5Ј-TCCATCCGACCT-GGTGCCAT-3Ј and reverse 5Ј-TTCTCCACGTCAGGCGTTG-3Ј, Pax3; forward 5Ј-CAACCAGGAGGAGCGCGATCTCCG-3Ј and reverse 5Ј-AGGCGCTGTGGGAGTT-GCATTCACT-3Ј, Myogenin; and forward 5Ј-CACCATCTTCCAGGAGCGAG-3Ј and reverse 5Ј-CCTTCTCCATGGTGGTGAAGA-3Ј, GAPDH. PCRs were per- formed with Power SYBR Green PCR Master Mix (Applied Biosystems). For protein analysis, cell lysates were prepared with 50 L of lysis buffer (1% Nonidet P-40, 0.15 M NaCl, 50 mM Tris) supplemented with Complete protease inhibitor mixture (Roche). Twenty micrograms of total protein were loaded into wells of NuPAGE NOVEX Bis-Tris Gels (Invitrogen). Western blots were performed with monoclonal anti-Pax3 (DSHB), anti-Pax7 (DSHB), antiTroponin T (Sigma), and anti-␤-tubulin (Chemicon) antibodies. Detection was by ECL Plus Western Blotting Detection System (GE Healthcare), and blots were directly processed on a Storm 840 Optical scanner (Amersham) with the exception of anti-Pax3 Western blots, which were exposed to Hyperfilm MP (Amersham). Densitometry was performed with ImageQuaNT software (Molecular Dynamics). Lentiviral Production. 293T cells were transfected with the pLentiPGKGFP constructs indicated above, pREV, VSVG, ⌬874 (kind gifts from G. Cossu, DIBIT Universita Vita-Salute San Raffaele, Milan), by using CaCl 2/Hepes-buffered saline precipitation. Twenty-four hours later, the medium was changed and collected after a further 48 h, filtrated through a 44-m filter, and concentrated by using Vivaspin 20 concentrators with a 50,000 molecular weight cutoff (Sartorius Biotech). Titers were calculated by GFP FACS analysis of transduced 293 cells.
Somite Explant Culture and Transduction. Mouse embryos were taken at E9.5 and treated with 0.1% trypsin, 0.25% pancreatin for 5 min at 4°C, as described in ref. 32 . The three most recently formed somites were transferred to a 200-L drop of medium (40% DMEM, 40% F12, 20% FBS). After 10 min, when somites had attached, plates were carefully transferred to the incubator. Twelve to 16 h later, somites were transduced with lentivirus expressing either GFP or GFP-miR-27b at a concentration of 1.0 ϫ 10 4 virus particles per L. Twenty-four hours after transduction, the lentivirus-containing medium was removed and replaced with 1 mL of fresh medium. Somites were cultured for a total of 3 days.
Immunofluorescence. Fixed somite explants or cultured Pax3 GFP/ϩ cells were permeabilized with 0.2% Triton, 50 mM NH 4Cl, and blocked by using 0.2% gelatin in PBS. Frozen transverse sections were treated as described in ref. 33 . Primary antibodies used were monoclonal anti-Pax3 (DSHB), monoclonal anti-Pax7 (DSHB), monoclonal anti-Troponin T (Sigma), polyclonal antiMyogenin (Santa Cruz), polyclonal Lbx1 (a kind gift from C. Birchmeier, Max Delbrü ck Center, Berlin-Buch, Germany), polyclonal anti-laminin (Sigma), and polyclonal anti-GFP (MBL). Fluorochrome conjugated secondary antibodies (Molecular Probes) were used for visualization and DAPI was included in the washing steps at 1:1,000 before mounting with Gel-Mount (Electron Microscopy Sciences).
Transgenesis. The transgenic plasmids indicated above were digested with IsceI, agarose gel-purified, and transgenic animals were obtained as described in ref. 34 . Three transgenic animals were obtained with the miR-27b transgene. Mice were crossed with the Pax3 Cre/ϩ line (35) to activate miR-27b expression in Pax3-positive cells. This is under the control of the CAG promoter and contains an EGFP reporter to verify activation after Cre-mediated recombination. Embryos were dated taking the day after mating as E0.5.
Muscle Regeneration. Adult 8-week-old male Swiss mice were anesthetized by i.p. injection of a mixture of Imalgene 1,000 (ketamine, 100 mg/mL, 10 mg/kg) and Rompun (xylazine, 2%, 0.06 mL/kg). Breast skin was opened in anesthetized mice, and pectoralis muscles were exposed and injected with a 100-L solution containing 10 M cardiotoxin and 10 g of either anti-miR-27 or negative control antagomirs (Dharmacon). Six days after injection, pectoralis muscles were dissected and immediately frozen in isopentane cooled in liquid nitrogen and stored at Ϫ80°C until analysis. Care and handling of animals were in accordance with the regulations of the French Ministry of Agriculture and Fisheries practiced by the Institut Pasteur animal facility.
